An Update on the Clinical Development of Proprotein Convertase Subtilisin Kexin 9 Inhibitors, Novel Therapeutic Agents for Lowering Low-Density Lipoprotein Cholesterol

Hua Ling; Tammy L. Burns; Daniel E. Hilleman

doi:10.1111/1755-5922.12056

An Update on the Clinical Development of Proprotein Convertase Subtilisin Kexin 9 Inhibitors, Novel Therapeutic Agents for Lowering Low-Density Lipoprotein Cholesterol

Hua Ling, Tammy L. Burns, Daniel E. Hilleman

Department of Pharmacy Practice

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Cardiovascular Therapeutics
Volume	32
DOIs	https://doi.org/10.1111/1755-5922.12056
State	Published - Apr 1 2014

Disciplines

Pharmacology
Cardiology
Internal Medicine
Medicine and Health Sciences
Endocrinology

Access to Document

10.1111/1755-5922.12056License: Unspecified

Cite this

@article{36a1c9187cbc43abbf1b4817c720eed8,

title = "An Update on the Clinical Development of Proprotein Convertase Subtilisin Kexin 9 Inhibitors, Novel Therapeutic Agents for Lowering Low-Density Lipoprotein Cholesterol",

author = "Hua Ling and Burns, {Tammy L.} and Hilleman, {Daniel E.}",

note = "Hua Ling Corresponding Author The Cardiac Center of Creighton University, Omaha, NE, USA Correspondence H. Ling, Pharm D., School of Pharmacy, Hampton University, 100 E Queen St, Hampton, VA 23668, USA.",

year = "2014",

month = apr,

day = "1",

doi = "10.1111/1755-5922.12056",

language = "American English",

volume = "32",

journal = "Cardiovascular Therapeutics",

}

TY - JOUR

T1 - An Update on the Clinical Development of Proprotein Convertase Subtilisin Kexin 9 Inhibitors, Novel Therapeutic Agents for Lowering Low-Density Lipoprotein Cholesterol

AU - Ling, Hua

AU - Burns, Tammy L.

AU - Hilleman, Daniel E.

N1 - Hua Ling Corresponding Author The Cardiac Center of Creighton University, Omaha, NE, USA Correspondence H. Ling, Pharm D., School of Pharmacy, Hampton University, 100 E Queen St, Hampton, VA 23668, USA.

PY - 2014/4/1

Y1 - 2014/4/1

UR - http://onlinelibrary.wiley.com/doi/10.1111/1755-5922.12056/full

U2 - 10.1111/1755-5922.12056

DO - 10.1111/1755-5922.12056

M3 - Article

VL - 32

JO - Cardiovascular Therapeutics

JF - Cardiovascular Therapeutics

ER -

An Update on the Clinical Development of Proprotein Convertase Subtilisin Kexin 9 Inhibitors, Novel Therapeutic Agents for Lowering Low-Density Lipoprotein Cholesterol

Disciplines

Access to Document

Other files and links

Cite this